Pamela Munster, MD
Enriched profileProfessor of Medicine (Oncology) and Associate Director for Early Detection and Interception Research, Stanford Cancer Institute · Stanford University
Pamela Munster is Professor of Medicine (Oncology) and Associate Director for Early Detection and Interception Research, Stanford Cancer Institute at Stanford University. OpenAlex indexes 755 publications with 20,323 citations (h-index 68); ClinicalTrials.gov lists 20 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 23 Oct 2026
Pamela Munster, MD, is Professor of Medicine (Oncology) and Associate Director for Early Detection and Interception Research, Stanford Cancer Institute at Stanford University. The public record shows 755 publications with 20,323 citations (h-index 68), centered on Cancer Immunotherapy and Biomarkers, PARP inhibition in cancer therapy, Advanced Breast Cancer Therapies. It also documents an investigator role on 20 registered clinical trials, industry payments reported by 13 companies, 6 NIH-funded awards (2008–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Cancer Immunotherapy and Biomarkers
- 20 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 205.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:
- Pilot Study of Pancreatic Cancer Screening
Sponsor: University of California, San Francisco
- A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Sponsor: AtlasMedx, Incorporated
Industry payments
Updated 23 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Corcept TherapeuticsProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor100%Letrozole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
6 NIH research awards on record, funded 2008–2026 per NIH RePORTER. The latest:
- Integrating Epigenetic Modulation into DNA Damage Repair
University of California, San Francisco
FY2026$658,659R01CA255613 - Integrating Epigenetic Modulation into DNA Damage Repair
University of California, San Francisco
FY2025$658,646R01CA255613 - Integrating Epigenetic Modulation into DNA Damage Repair
University of California, San Francisco
FY2024$625,664R01CA255613
Congress activity
Updated 23 Oct 2026
180 congress contributions (2004–2026) across AACR, ASCO, ASH, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 3843: Sequencing full-length mRNA in whole blood of breast cancer patients for antibody-drug conjugate therapy selection
AACR Annual Meeting
AACR2026Co-author - Abstract 6277: Determinants of Cancer Risk in Hereditary Cancer-Prone Individuals: The eGene Study.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.
Clinical cancer research
Clinical Trial2025 - Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
JCO precision oncology
Clinical Trial2024 - ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.
Cancer research communications
Clinical Trial2024 - A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
Cancer research communications
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01KRAS G12C Inhibition with Sotorasib in Advanced Solid TumorsArticle1,717 citations2020
- 02Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1- 13 C]PyruvateArticle1,286 citations2013
- 03Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic MelanomaArticle701 citations2008
- 04
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Editorial & leadership roles
journal and society appointments- Medical Oncology Approval Committees
Traditional 10-Year MOC Exam Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →abim.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medifind.com ↗
Secondary affiliations
appointments beyond the home institution- Helen Diller Family Comprehensive Cancer Center
University of California San Francisco (previous)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Heather Wakelee, MD
Stanford University
Julie Parsonnet, MD
Stanford University
Martha Morrell, MD
Stanford University
Alexander Sandhu, MD
Stanford University
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope